Journal Mobile Options
Table of Contents
Vol. 20, No. 3-4, 2002
Issue release date: 2002
Dig Dis 2002;20:284–288
(DOI:10.1159/000067682)

Assessment of Depression in Patients with Chronic Viral Hepatitis: Effect of Interferon Treatment

Koskinas J. · Merkouraki P. · Manesis E. · Hadziyannis S.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Introduction/Aim: Chronic viral hepatitis and its treatment with interferon (IFN) have an impact on patients’ quality of life. The purpose of this study was to evaluate the degree of depression in patients with chronic viral hepatitis before and during IFN therapy. Patients/Methods: Our study group comprised 132 patients, 38 with chronic hepatitis C (26 males, 12 females), 36 with chronic hepatitis B (29 males, 7 females), and 58 individuals with no chronic disease (24 males, 34 females). Depression was assessed using the Zung Self-Rating Depression Scale and the corresponding SDS index. Results: At baseline, patients with viral hepatitis and healthy controls had similar SDS indexes. During treatment, a significant increase in the SDS index was observed in both HBV and HCV patients (p < 0.001), which returned to the baseline levels after treatment. During IFN therapy, the SDS indexes were higher in HCV compared to HBV patients and women compared to men (p = 0.001 and p = 0.008, respectively), and there was a >5- fold increased frequency to develop severe depression. Conclusions: IFN-induced depression occurs more frequently in HCV than HBV patients and in women than men. Monitoring during treatment is mandatory in order to maximize treatment adherence.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Alter MJ: Epidemiology of hepatitis C. Hepatology 1997;26(suppl 1):62S–65S.
  2. Tong MJ, El-Farra NS, Reikes AR, Co RL: Clinical outcomes after transfusion associated hepatitis C. N Engl J Med 1995;332:1463–1466.
  3. Hadziyannis SJ: Hepatitis B e antigen negative chronic hepatitis B: From clinical recognition to pathogenesis and treatment. Viral Hepatitis Rev 1995;1:7–36.
  4. Davis GL, Esteban Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, Zeuzem S, Craxi A, Ling MH, Albrecht JK: Interferon alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998;339:1493–1499.
  5. Poynard T, Marcellin P, Lee S, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J: Randomized trial of interferon alfa-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426–1432.
  6. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK: Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485–1492.
  7. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodmann ZD, Koury K, Ling M, Albrecht J: Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial. Lancet 2001;358:958–965.
  8. Niederau G, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, Haussinger D: Long term follow-up of HBeAg-positive patients treated with interferon alpha for chronic hepatitis B. N Engl J Med 1996;334:1422–1427.
  9. Tine F, Liberati A, Graxi A, Almasio P, Pagliaro L: Interferon treatment in patients with chronic hepatitis B: A meta-analysis of the published literature. J Hepatol 1993;18:154–163.
  10. Wong JB, Koff RS, Tine F, Pauker SG: Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1995;122:664–675.
  11. Lin S, Sheen IS, Chien RN, Chu CM, Liaw YF: Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999;29:971–975.
  12. Hoofnagle JH, Di Bisceglie AM: The treatment of chronic viral hepatitis. N Engl J Med 1997;336:347–356.
  13. Dusheiko B: Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997;26(suppl 1):112S–121S.
  14. Janssen HLA, Brouwer JT, Van Der Mast RC, Schalm SW: Suicide associated with alpha interferon therapy for chronic viral hepatitis. J Hepatol 1994;21:241–243.
  15. Ademmer K, Beutel M, Bretzel R, Jaeger C, Reimer C, Clemens J: Suicidal ideation with interferon alpha and ribavirin in a patient with hepatitis C. Psychosomatics 2002;43:88.
  16. Zung WWK: The puzzle of depression diagnoses: A binomial solution; in Cavenaz JO, Brodie HKH (eds): Critical Problems in Psychiatry. Philadelphia, Lippincott, 1982, pp 157–179.
  17. Zung WWK: A self-rating depression scale. Arch Gen Psychiatry 1965;12:63–70.
  18. Arve S, Lauri S, Lehtonen A: Clinical pathway of elderly persons with lowered mood in the health care services. Scand J Caring Sci 2000;14:191–198.
  19. Deyo R, Patrick D: Barriers to the use of health status measures in clinical investigation, patient care and policy research. Med Care 1989;27:254S–268S.
  20. Pariante CM, Orru MC, Baita A, Farci MG, Carpiniello A: Treatment with interferon-α in patients with chronic hepatitis and mood or anxiety disorders. Lancet 1999;354:131–132.
  21. Ware JE, Bayliss MS, Mannocchia M, Davis GL: Health-related quality of life in chronic hepatitis C: Impact of disease and treatment response. Hepatology 1999;30:550–555.
  22. Younnosi ZB: Economic and quality-of-life measures in the study of viral hepatitis. Viral Hepatitis Rev 1999;5:101–111.
  23. Younossi ZM, Boparai N, McCormick M, Price LL, Guyatt G: Assessment of utilities and health-related quality of life in patients with chronic liver disease. Am J Gastroenterol 2001;96:579–583.
  24. Bonkovsky HL, Woolley JM, and the Consensus Interferon Study Group: Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. Hepatology 1999;29:264–270.
  25. Foster GR, Goldin RD, Thomas HC: Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998;27:209–212.
  26. Ware JA, Davis GL: Health related quality of life in chronic hepatitis C. Impact of disease and treatment response. Hepatology 1999;30:550–555.
  27. Fontana RJ, Moyer CA, Sonnad S, Lok ASF, Sneed-Pee N, Walsh J, Klein S, Webster S: Comorbidities and quality of life in patients with interferon-refractory chronic hepatitis C. Am J Gastroenterol 2001;96:174–177.
  28. Neary MP, Cort S, Bayliss MS, Ware JE: Sustained virologic response is associated with improved health related quality of life in relapsed chronic hepatitis C patients. Semin Liver Dis 1999;19:77–85.

    External Resources

  29. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, Zarski JP: Meta-analysis of interferon randomized trials in the treatment of viral hepatitis: Effects of dose and duration. Hepatology 1996;24:778–779.
  30. Scalori A, Apale P, Panizzuti F, Mascoli N, Pioltelli P, Pozzi M, Redaelli A, Roffi L, Mancia G: Depression during interferon therapy for chronic viral hepatitis: Early identification of patients at risk by means of a computerized test. Eur J Gastroenterol Hepatol 2000;12:505–509.
  31. Diepering E, Willenbring ML, Tetrick L, et al: Prospective evaluation of neuropsychiatric symptoms in patients with hepatitis C treated with interferon-alpha-2b and ribavirin (abstract). Gastroenterology 2002;122:T1412.

    External Resources

  32. Ware JE, Snow KK, Kosinski M, Gandek B (eds): SF-36 Health Survey Manual and Interpretation Guide. Boston, New England Medical Center and Health Institute, 1993.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50